MSI2 and myeloid leukemia: MSI2 was selected for further study from our original β-catenin interactome on the basis that the interaction was detected in at least two cell lines (reaching statistical significance in at least one subcellular fraction), had a low presence (<10%) in the contaminant repository for affinity purification (CRAP)ome database (present in 44/716 datasets indicating a low contaminant risk) [47], and has previously documented roles in myeloid leukaemia and the regulation of HSPC [48, 49].